Table 2.
Univariate and multivariate analyses affecting overall survival
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | 0.99 | 0.97–1.01 | 0.399 | |||
| ≥ 78 | 1 | |||||
| < 78 | 1.77 | 1.10–2.84 | 0.018 | |||
| Sex | ||||||
| Female | 1 | |||||
| Male | 1.66 | 1.11–2.47 | 0.013 | 1.51 | 1.01–2.28 | 0.047 |
| AACCI | ||||||
| ≤ 5 | 1 | |||||
| ≥ 6 | 1.67 | 1.13–2.47 | 0.010 | 1.56 | 1.06–2.31 | 0.026 |
| FEV1% | ||||||
| ≥ 50 | 1 | |||||
| < 50 | 1.06 | 0.72–1.58 | 0.762 | |||
| Histology | ||||||
| Unproven | 1 | |||||
| Proven | 1.16 | 0.79–1.69 | 0.457 | |||
| Adeno | 1.12 | 0.69–1.81 | 0.651 | |||
| Spino | 1.19 | 0.76–1.87 | 0.455 | |||
| PET | ||||||
| Yes | 1 | |||||
| No | 1.04 | 0.70–1.53 | 0.860 | |||
| Location | ||||||
| Peripheral | 1 | |||||
| Central | 1.29 | 0.72–2.30 | 0.394 | |||
| Prescribed BED 10 | ||||||
| ≥ 150 | 1 | |||||
| < 150 | 1.31 | 0.89–1.93 | 0.168 | 1.26 | 0.85–1.88 | 0.256 |
| Maximum BED 10 | ||||||
| ≥ 251.6 | 1 | |||||
| < 251.6 | 1.43 | 0.96–2.11 | 0.076 | |||
| T stage | ||||||
| T1a-c | 1 | |||||
| T2a-b | 1.43 | 0.97–2.11 | 0.073 | 1.08 | 0.90–1.29 | 0.411 |
(HR: hazard ratio, CI: confidence interval, AACCI: age-adjusted Charlson comorbidity index, FEV1: forced expiratory volume in 1 s, BED10: biologically effective dose with alpha/beta = 10 Gy)